<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321996</url>
  </required_header>
  <id_info>
    <org_study_id>CE119/2008/0/Sper</org_study_id>
    <nct_id>NCT01321996</nct_id>
  </id_info>
  <brief_title>68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with
      idiopathic pulmonary fibrosis, in particular in patients with a diagnosis of IPF/UIP
      (idiopathic pulmonary fibrosis, diagnosed based in the American Thoracic Society and European
      Respiratory Society criteria) and in forms of NSIP (non-specific interstitial pneumonia).
      PET/CT imaging data will be compared with HRCT (high-resolution computed tomography) findings
      to assess disease extension, early disease detection and to non-invasively detect
      somatostatin receptors expression at lung level in these patients, with potential therapeutic
      implications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis prognosis remains severe, in particular for IPF, the most
      common entity. Moreover, current treatment options are largely ineffective and do not change
      the natural course of the disease. Pre-clinical evidence supports somatostatin receptors
      expression in the lung of patients with IPF. Recently new PET tracers (Somatostatin analogues
      labelled with 68Gallium), specifically binding to somatostatin receptors, have been developed
      and are used in neuroendocrine tumours clinical trials.

      Aim of the present study is to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with
      idiopathic pulmonary fibrosis, in particular in patients with IPF/UIP and in cases with NSIP,
      that are characterized by a more indolent progression. PET/CT data will be compared with HRCT
      findings for the early detection of fibrotic areas and to non-invasively assess somatostatin
      receptors expression at lung level in these patients, with potential therapeutic
      implications. Moreover, the SUVmax (maximum standardized uptake value) will be analyzed in
      comparison with disease site and extension on HRCT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    enrollment failure (only 29 patients were enrolled during the study period)
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe pattern of 68Ga-DOTA-NOC uptake in comparison with HRCT findings</measure>
    <time_frame>timeframe between imaging procedures 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-DOTA-NOC SUVmax correlation with pulmonary function tests</measure>
    <time_frame>timeframe between PET/CT and pulmonary fucntion tests 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTANOC PET/CT in patients with IPF and NSIP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>one arm study: all patients were studied by 68Ga-DOTANOC PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>68Ga-DOTA-NOC PET/CT</intervention_name>
    <description>procedure: PET/CT scan with 68Ga-DOTA-NOC</description>
    <arm_group_label>68Ga-DOTANOC PET/CT in patients with IPF and NSIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of IPF and NSIP, based on the American Thoracic
             Society/European Respiratory Society Consensus Conference

          -  age â‰¥ 18 years

          -  males/females

          -  signed informed consent

        Exclusion Criteria:

          -  pregnancy

          -  breast feeding

          -  healthy volunteers

          -  paediatric cases

          -  patients in emergency situations

          -  patients legally incompetent

          -  patients who refuse to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Fanti, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola Malpighi, Bologna, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Ambrosini V, Zompatori M, De Luca F, Antonia D, Allegri V, Nanni C, Malvi D, Tonveronachi E, Fasano L, Fabbri M, Fanti S. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010 Dec;51(12):1950-5. doi: 10.2967/jnumed.110.079962. Epub 2010 Nov 15.</citation>
    <PMID>21078794</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Stefano Fanti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>68Ga-DOTANOC</keyword>
  <keyword>IPF</keyword>
  <keyword>NSIP</keyword>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

